Related Experiment Video

Updated: Aug 10, 2026

Identifying Protein-protein Interaction Sites Using Peptide Arrays
07:44

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Published on: November 18, 2014

Targeting protein-protein interactions in the BCL-2 family: opportunities for precision oncology

Vishnu Malakar1, Chandi C Malakar2, Pratap Chand Mali3

  • 1Department of Pharmacology,, JSS College of Pharmacy, Ooty, 643001, Tamil Nadu, India.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|August 8, 2026
PubMed

Insights

The B-cell lymphoma 2 (BCL-2) family regulates apoptosis and impacts cancer. Targeting BCL-2 with drugs like Venetoclax shows promise for cancer treatment, despite challenges like drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Apoptosis is crucial for cellular oxidative stress response and cancer development.
  • The B-cell lymphoma 2 (BCL-2) protein family controls the intrinsic apoptotic pathway.
  • Dysregulation of BCL-2 family proteins promotes tumor progression and treatment resistance.

Purpose of the Study:

  • To review the structure, function, and therapeutic relevance of the BCL-2 family in cancer.
  • To discuss BCL-2's role in apoptosis modulation and BH3 mimetic development.
  • To explore resistance mechanisms and combination strategies for BCL-2-targeted therapies.

Main Methods:

  • Systematic review of scientific literature.
  • Analysis of structural and functional data of BCL-2 family proteins.
  • Evaluation of preclinical and clinical data for BCL-2-targeted drugs.

Main Results:

  • BCL-2 family proteins are key regulators of apoptosis and are frequently altered in cancer.
  • BH3 mimetics, such as Venetoclax, demonstrate significant therapeutic potential.
  • Venetoclax shows improved efficacy and safety in various cancer types, often in combination therapies.

Conclusions:

  • The BCL-2 family represents a promising therapeutic target for cancer treatment.
  • Venetoclax and other BH3 mimetics offer effective treatment options, but resistance mechanisms require further investigation.
  • Future directions include biomarker-guided patient selection and development of next-generation BCL-2 inhibitors.
Keywords:
ApoptosisBCL-2 proteinsBH3-mimeticsCancer therapySDG 3 (Good Health and Well-being)

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...